Zacks Research Issues Pessimistic Forecast for EW Earnings

Edwards Lifesciences Co. (NYSE:EW) – Zacks Research decreased their Q1 2025 earnings estimates for Edwards Lifesciences in a research note issued to investors on Thursday, January 30th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $0.57 per share for the quarter, down from their previous forecast of $0.58. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share.

Several other equities research analysts have also weighed in on EW. Piper Sandler cut their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Citigroup increased their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Morgan Stanley reissued an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a research report on Friday, October 11th. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Finally, Truist Financial reaffirmed a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $79.19.

Edwards Lifesciences Trading Down 0.1 %

EW opened at $71.33 on Monday. The firm’s fifty day moving average is $72.49 and its two-hundred day moving average is $69.63. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market cap of $42.07 billion, a PE ratio of 10.29, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,000 shares of company stock worth $547,430. 1.27% of the stock is owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently bought and sold shares of the company. Harbor Capital Advisors Inc. increased its holdings in Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after buying an additional 273 shares during the period. Nordea Investment Management AB increased its position in Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after purchasing an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its position in Edwards Lifesciences by 6.7% during the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock worth $355,344,000 after purchasing an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $3,702,000. Finally, Avanza Fonder AB acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $4,845,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.